/
ADGM
$0.65+$0.01 (+0.81%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$14.3M
22M shares
52-week range
$0.62 – $2.58
2% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
51.69%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-8.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $270.0K | $189.0K | $300.0K | $269.0K | $0 |
| Cost of revenue | $0 | $1.2M | $875.0K | $1.3M | $1.9M | $684.0K |
| Gross profit | $0 | −$888.0K | −$686.0K | −$1.0M | −$1.7M | −$684.0K |
| Gross margin | — | -328.9% | -363.0% | -335.3% | -620.1% | — |
| R&D | $0 | $15.4M | $17.9M | $15.4M | $4.6M | $10.6M |
| Operating income | −$13.5K | −$20.6M | −$23.9M | −$27.9M | −$62.5M | −$21.9M |
| EBITDA | −$13.5K | −$19.6M | −$23.0M | −$27.4M | −$53.5M | −$21.2M |
| Net income | −$13.5K | −$19.9M | −$23.7M | −$38.1M | −$53.8M | −$25.1M |
| Net margin | — | -7384.4% | -12525.4% | -12715.3% | -19986.2% | — |
| EPS (diluted) | -0.00 | -0.34 | 0.06 | -4.86 | -3.54 | -1.51 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.18 | $-1.54–$-0.84 | 1 |
| 2027 | $2M | $-1.35 | $-1.76–$-0.96 | 2 |
| 2028 | $7M | $-1.56 | $-2.99–$-0.36 | 3 |
| 2029 | $20M | $-3.32 | $-4.34–$-2.37 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Adagio Medical Holdings, Inc Common Stock
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
www.adagiomedical.com- Employees
- 41
- IPO / List date
- Aug 1, 2024
- HQ
- LAGUNA HILLS, CA
Held by traders on TradeandTell
No one on the platform currently holds ADGM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 16,557 | $19.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ADGM yet.
